The information highlighted (if any) are the most recent updates for this brand.
Afatinib dimaleate (Giotrif) is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.